-
Sun Pharma to Acquire Checkpoint Therapeutics
-
D. Boral Capital Starts Checkpoint Therapeutics (CKPT) at Buy
-
Increasing unusual call option volume: QBTS SKYT QUBT RCNC XP RGTI SLQT KULR TEVA UAA CKPT
-
Increasing unusual call option volume: CKPT BZUN QUBT RVNC RCAT BIRK GALT ASAN
-
Checkpoint Therapeutics (CKPT) PT Raised to $7 at Lake Street Capital Markets
-
Checkpoint Therapeutics (CKPT) Misses Q3 EPS by 23c
-
Checkpoint Therapeutics (CKPT) Presents Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma
-
Checkpoint Therapeutics (CKPT) Files for 5.85M Share Offering by Selling Stockholders
-
Checkpoint Therapeutics (CKPT) PT Lowered to $20 at H.C. Wainwright
-
Checkpoint Therapeutics (CKPT) Misses Q2 EPS by 18c
-
Checkpoint Therapeutics (CKPT) Announces FDA Acceptance of BLA Resubmission of Cosibelimab
-
H.C. Wainwright Reiterates Buy Rating on Checkpoint Therapeutics (CKPT)
-
Checkpoint Therapeutics (CKPT) Announces 5.85M Share Offering at $2.05/sh
-
Checkpoint Therapeutics (CKPT) Announces BLA Resubmission for Cosibelimab
-
Checkpoint Therapeutics (CKPT) Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission

